XRCC1与晚期非小细胞肺癌含铂类药物化疗疗效的关系  

Relationship of XRCC1 and efficacy of platinum-based chemotherapy in advanced non-small cell lung cancer

作　　者：盛桂凤[1] 毕延智[1] 刘永萍[1] 董益忠[1] 宋红蕾[1] 凌扬[1] 张亚平[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,江苏省213001

出　　处：《江苏医药》2013年第3期295-297,共3页Jiangsu Medical Journal

基　　金：江苏省卫生厅医学科技发展基金(P200935);常州市卫生局重大科技项目(ZD200913)

摘　　要：目的探讨X线修复交叉互补基因1(XRCC1)与接受含铂方案化疗的晚期非小细胞肺癌(NSCLC)患者的近期疗效的关系。方法经病理确诊的晚期NSCLC患者62例,接受含铂方案化疗至少2个周期后评价疗效。采用TaqMan探针FQ-PCR法和直接测序法对患者外周血XRCC1第399位密码子进行多态性分析,分析各基因型与晚期NSCLC患者近期疗效及不良反应的的相关性。结果 XRCC1 399至少携带一个Gln等位基因携带者的疗效不如Arg等位基因携带者(14.81%vs.42.86%)(P<0.05)。XRCC1不同基因型与化疗不良反应无明显相关性。结论 XRCC1 399多态性与NSCLC患者对铂类药物化疗的敏感性相关。Objective To study the relationship of XRCC1 and short-term efficacy of platinum-based chemotherapy in advanced non-small cell lung cancer（NSCLC）.Methods A total of 62 patients with advanced NSCLC diagnosed by pathology was treated with cisplatin or carboplatin-based chemotherapy.The clinical response was evaluated after at least 2 therapeutic cycles.Single nuclear polymorphism in XRCC1 Arg399Gln was assessed by FQ-PCR with TaqMan test needle and direct sequencing.The relationship of genotypes with short-term efficacy and toxicic response to platin-based chemotherapy was analyzed.Results The effectiveness rate of chemotherapy was significantly higher in the patients with the 399 Arg/Arg genotype than that with the Arg/Gln and Gln/Gln genotype（14.81% vs.42.86%）（P0.05）.There was no statistical correlation between the toxicity to chemotherapy and different genotypes of XRCC1 399（P0.05）.Conclusion Polymorphism of XRCC1 399 is associated with the sensibility of NSCLC patients to platin-based chemotherapy.

关 键 词：非小细胞肺癌 X线修复交叉互补基因1 化疗 

分 类 号：R734[医药卫生—肿瘤]